Found: 145
Select item for more details and to access through your institution.
Injectable antiretroviral therapy: best practice guide for nurses providing care to people living with HIV.
- Published in:
- British Journal of Nursing, 2024, v. 33, n. 11, p. S12, doi. 10.12968/bjon.2024.0146
- By:
- Publication type:
- Article
Cardiovascular disease, medication regimens and HIV in pregnancy: new research relevant to nurses 1.
- Published in:
- 2024
- By:
- Publication type:
- Proceeding
Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.
- Published in:
- AIDS Patient Care & STDs, 2024, v. 38, n. 6, p. 275, doi. 10.1089/apc.2024.0067
- By:
- Publication type:
- Article
Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV.
- Published in:
- HIV Medicine, 2024, v. 25, n. 6, p. 684, doi. 10.1111/hiv.13617
- By:
- Publication type:
- Article
Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.
- Published in:
- AIDS Patient Care & STDs, 2024, v. 38, n. 5, p. 221, doi. 10.1089/apc.2024.0048
- By:
- Publication type:
- Article
Implementation of a Pharmacist-Led, Long-Acting, Injectable Cabotegravir/Rilpivirine Program for HIV-1 at Health System-Based Clinics in the New York Metropolitan Area.
- Published in:
- AIDS Patient Care & STDs, 2024, v. 38, n. 3, p. 115, doi. 10.1089/apc.2023.0250
- By:
- Publication type:
- Article
Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy.
- Published in:
- Clinical Infectious Diseases, 2024, v. 78, n. 1, p. 122, doi. 10.1093/cid/ciad511
- By:
- Publication type:
- Article
Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine.
- Published in:
- AIDS Research & Therapy, 2024, v. 21, n. 1, p. 1, doi. 10.1186/s12981-023-00590-4
- By:
- Publication type:
- Article
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
- Published in:
- Clinical Infectious Diseases, 2023, v. 77, n. 10, p. 1423, doi. 10.1093/cid/ciad370
- By:
- Publication type:
- Article
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.
- Published in:
- HIV Medicine, 2023, v. 24, n. 11, p. 1126, doi. 10.1111/hiv.13542
- By:
- Publication type:
- Article
Trend over time of HIV‐1 drug resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and their drivers: A cohort study from Antiviral Response Cohort Analysis (ARCA).
- Published in:
- HIV Medicine, 2023, v. 24, n. 11, p. 1150, doi. 10.1111/hiv.13525
- By:
- Publication type:
- Article
Best Practices in the Treatment and Management of HIV: An In-Depth Look at ART Decision Making Strategies for Optimized Clinical and Economic Outcomes.
- Published in:
- Journal of Managed Care Medicine, 2023, v. 26, n. 4, p. 23
- By:
- Publication type:
- Article
Heart transplantation and human immunodeficiency virus–navigating drug-drug interactions: a case report.
- Published in:
- AIDS Research & Therapy, 2023, v. 20, n. 1, p. 1, doi. 10.1186/s12981-023-00551-x
- By:
- Publication type:
- Article
Efficacy and safety of dolutegravir/rilpivirine in real‐world clinical practice. GeSIDA study 1119.
- Published in:
- HIV Medicine, 2023, v. 24, n. 8, p. 933, doi. 10.1111/hiv.13489
- By:
- Publication type:
- Article
Acceptance Rate and Reasons for Rejection of Long Acting Injectable Antiretrovirals.
- Published in:
- AIDS & Behavior, 2023, v. 27, n. 7, p. 2370, doi. 10.1007/s10461-022-03964-3
- By:
- Publication type:
- Article
High Acceptability and Perceived Feasibility of Long-Acting Injectable Antiretroviral Treatment Among People Living with HIV Who Are Viremic and Health Workers in Uganda.
- Published in:
- AIDS Patient Care & STDs, 2023, v. 37, n. 6, p. 316, doi. 10.1089/apc.2023.0017
- By:
- Publication type:
- Article
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 9, p. 1646, doi. 10.1093/cid/ciad020
- By:
- Publication type:
- Article
Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 7, p. 1225, doi. 10.1093/cid/ciac901
- By:
- Publication type:
- Article
Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real‐world setting in Belgium.
- Published in:
- HIV Medicine, 2023, v. 24, n. 3, p. 267, doi. 10.1111/hiv.13373
- By:
- Publication type:
- Article
Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition.
- Published in:
- Cancers, 2023, v. 15, n. 4, p. 1044, doi. 10.3390/cancers15041044
- By:
- Publication type:
- Article
First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 3, p. e645, doi. 10.1093/cid/ciac631
- By:
- Publication type:
- Article
Human Immunodeficiency Virus Type 1 RNA Levels in Rectal and Seminal Compartments After Switching to Long-Acting Cabotegravir Plus Rilpivirine: A Longitudinal Study.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 3, p. e748, doi. 10.1093/cid/ciac676
- By:
- Publication type:
- Article
Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV‐1 in need of parenteral antiretroviral therapy.
- Published in:
- HIV Medicine, 2023, v. 24, n. 2, p. 202, doi. 10.1111/hiv.13370
- By:
- Publication type:
- Article
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial.
- Published in:
- AIDS Patient Care & STDs, 2023, v. 37, n. 1, p. 53, doi. 10.1089/apc.2022.0168
- By:
- Publication type:
- Article
Long-Acting Antiretroviral Drug Therapy in Adolescents: Current Status and Future Prospects.
- Published in:
- Journal of the Pediatric Infectious Diseases Society, 2023, v. 12, n. 1, p. 43, doi. 10.1093/jpids/piac134
- By:
- Publication type:
- Article
BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022.
- Published in:
- HIV Medicine, 2022, v. 23, p. 3, doi. 10.1111/hiv.13446
- By:
- Publication type:
- Article
Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series.
- Published in:
- AIDS Research & Therapy, 2022, v. 19, n. 1, p. 1, doi. 10.1186/s12981-022-00477-w
- By:
- Publication type:
- Article
Importance of multidisciplinary collaboration for smooth kidney transplantation in HIV-infected patients with chronic kidney disease: a case report.
- Published in:
- Renal Replacement Therapy, 2022, v. 8, n. 1, p. 1, doi. 10.1186/s41100-022-00435-2
- By:
- Publication type:
- Article
Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.
- Published in:
- HIV Medicine, 2022, v. 23, n. 8, p. 849, doi. 10.1111/hiv.13268
- By:
- Publication type:
- Article
Observational cohort study of rilpivirine (RPV) utilization in Europe.
- Published in:
- AIDS Research & Therapy, 2022, v. 19, n. 1, p. 1, doi. 10.1186/s12981-022-00457-0
- By:
- Publication type:
- Article
Eficacia en vida real del cambio a bictegravir/emtricitabina/tenofovir alafenamida en pacientes previamente tratados con pautas triples que contienen rilpivirina.
- Published in:
- Revista Española de Quimioterapia, 2022, v. 35, n. 4, p. 378, doi. 10.37201/req/013.2022
- By:
- Publication type:
- Article
Cabotegravir and Rilpivirine Long-acting Injectable Therapy for Human Immunodeficiency Virus.
- Published in:
- touchREVIEWS in Infectious Diseases, 2022, v. 1, n. 1, p. 14, doi. 10.17925/ID.2022.1.1.14
- By:
- Publication type:
- Article
Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS).
- Published in:
- AIDS Research & Therapy, 2021, v. 18, n. 1, p. 1, doi. 10.1186/s12981-021-00402-7
- By:
- Publication type:
- Article
Cabotegravir-Rilpivirine: The First Complete Long-Acting Injectable Regimen for the Treatment of HIV-1 Infection.
- Published in:
- Annals of Pharmacotherapy, 2021, v. 55, n. 11, p. 1397, doi. 10.1177/1060028021995586
- By:
- Publication type:
- Article
Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials.
- Published in:
- Clinical Infectious Diseases, 2021, v. 73, n. 8, p. 1440, doi. 10.1093/cid/ciab444
- By:
- Publication type:
- Article
Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real‐world evidence.
- Published in:
- HIV Medicine, 2021, v. 22, n. 6, p. 423, doi. 10.1111/hiv.13050
- By:
- Publication type:
- Article
Analytical Method Development and Validation of Rilpivirine by RP-HPLC Method.
- Published in:
- International Journal of Pharmaceutical Research (09752366), 2021, v. 13, n. 3, p. 368, doi. 10.31838/ijpr/2021.13.03.066
- By:
- Publication type:
- Article
Changes in serum concentration of rilpivirine in an HIV-infected patient treated with a combination therapy of hemodialysis and peritoneal dialysis.
- Published in:
- Renal Replacement Therapy, 2020, v. 6, n. 1, p. 1, doi. 10.1186/s41100-020-00282-z
- By:
- Publication type:
- Article
Cabotegravir Plus Rilpivirine: First Approval.
- Published in:
- Drugs, 2020, v. 80, n. 9, p. 915, doi. 10.1007/s40265-020-01326-8
- By:
- Publication type:
- Article
Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults.
- Published in:
- AIDS Research & Therapy, 2020, v. 17, n. 1, p. 1, doi. 10.1186/s12981-020-00272-5
- By:
- Publication type:
- Article
Effects of ursodeoxycholic acid on rilpivirine plasma trough concentrations: a case report.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
- Published in:
- AIDS Research & Therapy, 2020, v. 17, n. 1, p. 1, doi. 10.1186/s12981-020-0258-7
- By:
- Publication type:
- Article
Evaluation of kidney function in HIV‐infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine.
- Published in:
- HIV Medicine, 2019, v. 20, n. 10, p. 648, doi. 10.1111/hiv.12784
- By:
- Publication type:
- Article
Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice.
- Published in:
- AIDS Research & Therapy, 2019, v. 16, n. 1, p. N.PAG, doi. 10.1186/s12981-019-0222-6
- By:
- Publication type:
- Article
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Dolutegravir/Rilpivirine: A Review in HIV-1 Infection.
- Published in:
- Drugs, 2018, v. 78, n. 16, p. 1741, doi. 10.1007/s40265-018-1005-4
- By:
- Publication type:
- Article
Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials.
- Published in:
- HIV Medicine, 2018, v. 19, n. 10, p. 724, doi. 10.1111/hiv.12664
- By:
- Publication type:
- Article
Vismodegib treatment in a HIV positive patient on antiretroviral therapy.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Drug–Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
- Published in:
- Clinical Infectious Diseases, 2018, v. 67, n. 6, p. 934, doi. 10.1093/cid/ciy201
- By:
- Publication type:
- Article